We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Jimmy Zhang is a Venture Partner at LAV (Lilly Asian Ventures). He was former Vice President (global level), Transactions, Johnson & Johnson Innovation. He led the transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, as well as fund relationship and partnership in the region. Before joining J&J, Jimmy was the Managing Director, MSD Early Investments – Greater China at Merck & Co., and a member of Merck Research Lab (China) Senior Leadership Team. He was in charge of Merck's venture capital investments, licensing, acquisitions, external research collaboration, and alliance/partnership management in Greater China. He was also a Board Director of BeiGene (Beijing) Co, Ltd. (NASDAQ: BGNE) and an Advisor Board member of Cenova Ventures.
Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage companies in drug discovery in small and large molecules, vaccine, gene therapy, diagnostics, and healthcare IT. Jimmy was responsible for the investment, business development and operations of Synergenics and some of its portfolio companies, and their businesses in China. Jimmy was previously a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, managing director of cross-border investment at CL Investment Group and President and CEO of CL Life Sciences (Shenzhen) Ltd., and a project manager at Chiron Corporation (now part of Novartis).
Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition.
Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents. Jimmy is a founding member and former Chairman of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, judges to State Thousand Talents Program, Guangzhou Innovation Talents, Chengdu Jing Rong Hui Venture Road Show and CHIC Business Plan Competition, a faculty member of Venture Capital Institute (China) and a guest/adjunct professor at Tongji University, Shanghai and Yeehong Business School at Shenyang Pharmaceutical University. Jimmy is a frequently invited speaker and panelist at bio-pharma conferences and hi-tech meetings on investment, business development and doing business between US and China. He is often quoted in both US and Chinese news media.
This speaker's sessions: